🧾 What This Document Is

This is a DEF 14A, or Proxy Statement, for Caris Life Sciences. You can think of it as a detailed invitation and information packet for the company's upcoming annual shareholder meeting. Its main job is to give shareholders the info they need to vote on important company matters.

👉 In simple terms: This document explains who is running the company, how they are paid, who owns the stock, and what key decisions shareholders need to vote on. It's required by the SEC before a shareholder vote.

🏢 What The Company Does

Caris Life Sciences, Inc. (CAI) is a precision medicine company focused on cancer. They develop and use advanced molecular and genomic profiling tests to help doctors match cancer patients with the right treatments. They operate in the high-stakes, fast-moving world of oncology diagnostics.

👉 The big picture: Their mission is to use detailed genetic information from a patient's tumor to improve cancer care, a field often called "precision oncology."

💰 Executive Compensation Snapshot

The filing details how much the top executives were paid in 2025. The numbers are substantial, especially for the founder.

• David Dean Halbert (CEO & Chairman): Total compensation was $20.4 million. This included a $765k salary, a $3.26 million bonus, and $15.4 million in stock awards (RSUs).
• David Spetzler (President): Total compensation was $11.6 million, including $612k salary, a $704k bonus, and over $10 million in combined stock and option awards.
• J. Russel Denton (General Counsel): Total compensation was $5.4 million.

👉 Why it matters: These figures, especially the large equity awards, show the company is heavily using stock to reward and align its top leaders with shareholder performance as it grows as a public company.

🚀 Key Moves & Board Changes

This proxy outlines several significant changes in the company's leadership and governance structure.

• Board Refresh: The board is shrinking from 12 to 10 members. Two long-serving directors, Dr. George Poste and Dr. Jonathan Knowles, are retiring under the board's new retirement age policy.
• New Faces: The board has recently added two directors with deep industry expertise: David Fredrickson (EVP at AstraZeneca's oncology unit) and Dr. Jeffrey Vacirca (a practicing oncologist and CEO of a cancer care network).
• New Lead Independent Director: In 2025, Peter M. Castleman was appointed as the lead independent director, a role with specific duties to oversee the board and ensure independent oversight of management.

👉 What this signals: The changes suggest a board in transition post-IPO, bringing in fresh, relevant expertise (especially in oncology and large pharma) while implementing more structured governance.

📦 Stock Ownership & Power

The "who owns what" section reveals where control of the company lies.

• Founder Control: Founder and CEO David Dean Halbert owns about 44% of the company's shares. This is an enormous stake that gives him significant influence.
• Major Institutional Investors: Several large investment firms hold major stakes:
  • FMR LLC (Fidelity): 10.8%
  • Sixth Street affiliates: 6.9%
  • J.H. Whitney affiliates: 6.5%

👉 Why it matters: Despite being a public company, David Halbert's near-majority ownership means he retains tremendous control over corporate decisions and the company's direction.

⚖️ Governance & The Vote

Shareholders are being asked to vote on two main proposals at the June 4, 2026, virtual meeting.

1. Election of 10 Directors: The board recommends voting FOR all 10 nominees listed.
2. Ratify the Auditor: Shareholders are asked to approve the selection of Deloitte & Touche LLP as the independent accounting firm for 2026. The board also recommends a FOR vote here.

The company has also adopted strict policies prohibiting executives and directors from hedging the company's stock and requires pre-approval for pledging shares as loan collateral.

🔮 What's Next

As an "emerging growth company," Caris has reduced reporting requirements. This proxy statement is more limited in its executive compensation disclosure than what would be required from a larger, more mature company. The focus now is on executing its strategy as a newly public company in the competitive precision oncology space, with a board refreshed for this next phase.

🧠 The Analogy

Think of Caris Life Sciences like a cutting-edge Formula 1 racing team. David Halbert is the team principal and lead driver who founded the team and still owns a huge chunk of it. The proxy statement is like the pre-race briefing: it shows you the team's technical leadership (the board), how much the star drivers and engineers are paid (executive comp), who the major sponsors are (institutional investors), and the specific strategy calls (voting proposals) for the next race. The recent board changes are like upgrading the aerodynamics engineer and adding a veteran race strategist from a rival team.

🧩 Final Takeaway

This filing shows Caris Life Sciences as a founder-led, post-IPO company formalizing its governance. The massive stock ownership and compensation of CEO David Halbert highlight his central role, while the board changes and new policies signal a shift towards more structured public company oversight. Shareholders are being asked to ratify this leadership team and its chosen auditor for the road ahead.